Benitec Biopharma Inc. (NASDAQ: BNTC) will present interim clinical results from its Phase 1b/2a study of BB-301 at the American ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE